ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

Non- Invasive Tests in Related to NAFLD and NASH

Received: 25 October 2022, **Revised:** 27 November 2022, **Accepted:** 30 December 2022

Jaspreet Kaur Gujral [1], Dr. Busi Karunanand[2], Dr. Monu Sarin[3], Dr. Abhishek Gaurav[4]

1 Research Scholar , Department of Biochemistry SGT Medical College, Hospital and Research Institute Budhera, Gurugram, Email id- jaspreetkaur1284@gmail.com
2 HOD in department of biochemistry Department of Biochemistry SGT Medical College, Hospital and Research Institute Budhera, Gurugram. Email id- karunanandbusi@gmail.com
3 Professor in department of radiology Department of Radiology SGT Medical College, Hospital and Research Institute Budhera, Gurugram
4 Assistant professor in department of medicine , Department of Medicine SGT Medical College, Hospital and Research Institute Budhera, Gurugram

Keywords
NADFLD, NASH, FATTY LIVER, DYSLIPIDEMIA

Abstract
Background
Because of poor eating habits, weight increase, sedentary lifestyles, "Non-alcoholic fatty liver disease" the prevalence and incidence of (NAFLD)have risen over time. This Article aims to demonstrate how biomarkers can be used as early diagnostic tools to identify (NAFLD)or, patients suffering from disease of non-alcoholic fatty liver and (NASH) or, non-alcoholic steatohepatitis as well as the patient's subgroup with the fittest candidates for clinical trials on new compounds. NAFLD defines as the presence of hepatic steatosis of less than 5% in a histological examination without any evidence of hepatocellular injury, such as hepatocyte ballooning. It is frequently related to one or more metabolic syndrome components, such as dyslipidemia, diabetes mellitus, and obesity.
The most reliable method so far for diagnosing fatty liver(PDFF) or, proton density fat fraction generated from(MRI) or, magnetic resonance imaging. Clinical practice is the key issueinhow to make an early diagnosis of NASH. Despite a number of well-known limitations, most research on NASH confirm that point shear wave elastography or, transient elastography can help in increasing the individual number that should be tested for investigational therapy.

1. Introduction

Chronic liver illnesses, including fatty liver, fibrosis, and (NASH) non-alcoholic steatohepatitis is referred to as Non-alcoholic Fatty Liver Disease (NAFLD). The phrase "NAFLD" defines a common histological transition of "simple steatosis to steatohepatitis (NASH) and fibrosis-related NASH" [1].
NASH along with NAFLD are asymptomatic until the severe situation of the disease, and various individuals are only discovered at progressive stages; as a result, modifying risk factors and using current or experimental treatments are futile. Consequently, it is necessary to look at early predictors [2].

Biopsy of the liver is currently at the standard of gold for prognosis and diagnosis, but so costly procedure of invasion with a chance of sample error at a higher level. Other potential side effects include bleeding, discomfort, and, death in some extremely rare cases. There need urgency for accurate, dependable, minimally invasive or biomarkers of non-invasive because to the low patient acceptance of this invasive conventional procedure. With the lower acceptance level among patients for conventional invasive procedures, there isa need for biomarkers such as minimally invasive, dependable, and accurate.

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

Several minimally invasive tests or non-invasive testscan eliminate cirrhosis or, fibrosis and can help with the early diagnosis of NASH, but there is no one test that can detect steatosis or predict the course of the illness. In addition, to get access to the treatment response specialized test along with coupled tests are required during clinical trials on the compounds of appear.

2. Non- Invasive tests of Hepatic steatosis-

Historical Biomarkers-Liver enzymes by themselves are not trustworthy or precise indicators. Furthermore, even though inadvertently abnormal liver tests in patients with NAFLD are frequently documented [3,4], about 80% of patients with NAFLD may still have normal liver enzymes [5]. Patients with severe liver disease also have lower levels of alanine aminotransferase. [6,7]. Lastly, liver histology in NAFLD normal ALT patients is identical to that in those with abnormal enzymes of liver [8].

The score of the NAFLD Liver Fat (NLFS)evaluating the quantification of the fat content of the liver, which is showing a tolerable degree of NAFLD diagnostic accuracy. In the computation, type 2 diabetes, metabolic syndrome, fasting serum insulin, and the ratio ofalanine aminotransferase/serum aspartate aminotransferase are all taken into account (AAR). A sensitivity rate of 86% along with a71% of specificity, a score greater than 0.640 in a cohort of 470 individuals predicted NAFLD. The sensitivity for the prediction of NAFLD using cut-off scores of 1.413 and 1.257 is 95% (with 52% and 51% specificity, respectively) [9]. The formula's wider clinical application may be constrained by including the level of serum insulin, which shows it is not a standard test.

Using data from a significant cohort of Korean patients, HIS, or, Hepatic Steatosis Index, integrates data on the ratio of ALT/AST, diabetes, BMI, and gender, was validated versus ultrasound, which may be dependent on the operator. Thus, it showed a sensitivity of 66% and a specificity of 69%. [10]. In diabetic people, it seems to perform less well.

The waist size, serum triglyceride, BMI ,and gamma-glutamyl transferase or,(GGT)values make up Fatty Liver Index (FLI) [11]. While being authenticated against ultrasonography rather than histology of the liver. it has demonstrated good performance in the detection of fatty liver. 2.methods of non-invasive for diagnosing NAFLD.

Magnetic Resonance Imaging –A precise and reproducible method using sophisticated magnetic resonance imaging (MRI) can be used to quantify the density of proton fat fraction “(PDFF)”,a quantitative indicator and an objective of deposited hepatic fat throughout the liver [12,13,14,15]. Hepatic steatosis can be graded in adults with “non-alcoholic steatohepatitis”(NASH) and reduce mistakes caused by factors such as T2* decay,T1 bias, and the effects of fat protons on multifrequency signal interference that causes confusion with standard MRI for fat quantification, for determining to continue changes in hepatic fat “MRI-PDFF” is regarded as the most trusted method [16].In addition, MRI-PDFF in clinical trials has been shown to be more sensitive to detecting the changes in the content of hepatic fat and the response of treatment when compared to liver histology. Ezetimibe medication study demonstrated a correlation between histological results in NASH patients and with 29% decrease in the fat of liver on MRI-PDFF[17].IIb study included113 adult patients within a multi-center phase are randomized to receive placebo or, obeticolic acid,using central histology steatosis was assessed at baseline and using MRI-PDFFat treatment week 72 at various locations. Hepatic steatosis alterations, and grades can be correctly classified by MRI-PDFF, as has been shown [18].

CAP- A commercial ultrasound-based method called transient elastography (TE) evaluates stiffness in the liver as a stand-in for “hepatic fibrosis”. A method called the “controlled attenuation parameter” (CAP) makes it possible to detect stiffness and steatosis at the same time. Current research has demonstrated that in patients with considerable steatosis,the median CAP is higher and that there is a significant correlation between the steatosis grade and the steatosis percentage, and the CAP. A 2012 study [19,20] showed a significant connection (r = 0.81) between the level of steatosis and CAP. De Ledighen et al. have found that all metabolic syndrome indices and CAP values were significantly correlated in a huge study based on above 5300 tests [21]. In a research using both liver histology and CAP on 265 individuals, Ledighen obtained AUROC values of 0.80 for grade 2 steatosis and 0.66 for grade 3 steatosis [21]. 310 as acut-off value of Decibel per meter (dB/m), S2 steatosis had a positive guessing value of 86%, and 71% of the predictive value related

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

to negative. Additional histological correlation is needed in a large-scale study, of NAFLD patients for establishing thresholds of diagnostic. In conclusion, MRI-PDFF is establishing itself as the top biomarker for measuring liver fat that is based on comparisons with the histology of the liver. MRI-PDFF can correctly detect baseline and monitor changes in liver fat after experimental therapies. A simple, initial screening method in the general population could be the CAP evaluation.

3. Techniques for Diagnosing NASH

A French study found that 10% of 125,052 NAFLD/NASH patients who were hospitalized at the time of their diagnosis had compensated cirrhosis or decompensated cirrhosis. However, in the case of rapid progression, NASH was related, and over the course of 7 years, “27.5% of people with compensated disease progressed to decompensated cirrhosis”[22]. The significance of this backdrop emphasizes the need for serum diagnostics that are only minimally invasive in order to detect fibrosis associated with NASH at an early stage. Comparing the performance of liver histology with non-invasive fibrosis indicators is essential. Steatohepatitis has been extensively studied, although with only moderate accuracy [23], for fragment levels of plasma cytokeratin 18 or,(CK18), a marker of death related to hepatocyte. In order to determine whether NASH is present or absent, the Nash Test, a proprietary test, combines 13 clinical and biochemical factorssuch as “sex, height, age, weight, and serum levels of triglycerides (TGs), a-macroglobulin, apolipoprotein A1,cholesterol, haptoglobin, AST, ALT, total bilirubin and GGT”. This test requires many criteria that are not frequently assessed, which results in utilization restrictions. It achieves sensitivity, specificity, and (PPV)positive predictive value.

Using a model that took into account diabetes, gender, BMI, triglycerides, and other variables, evaluated people with biopsy-proven NASH[27]. The use of citokeratin markers such as M30 or, apoptosis and M65-M30 or, necrosis was uncommon. The same predictors were employed in the NASH-related fibrosis prediction model, which had an AUC of 0.80 with a 95% confidence interval of 0.68 to 0.88. The NASH-related advanced fibrosis model (AUC: 0.81, 95% CI, 0.70-0.89; p-value, 0.000062) includes blood triglycerides, type 2 diabetes, metalloprotease-1tissue inhibitor, and AST [27]. During the past15 years, the development of a huge number of minimally invasive blood testing has happened. Each of the Serum biomarkers is considered as assessing liver fibrosis performs better in later phases as compared to early stages.

Useful Blood Markers for the Diagnosis of NASH - Serum indicators for hepatic metabolism seen in the Increased Liver Fibrosis (ELF) panel are not often accessible (Table 1). In both adult and Pediatric NAFLD patients, ELF had been demonstrated in reliability to predict advanced fibrosis [28].

Serum indicators for hepatic metabolism that are not typically available are part of the Enhanced Liver Fibrosis (ELF)panel (Table 1). ELF has been shown reliability to predict advanced fibrosis in both juvenile NAFLD, and adult patients [28].

While liver histology is used as a reference standard to validate the performance of fibrosis of invasive markers, non-invasive imaging-based modalities such as UltraSound (US)-based elastographyand Transient Elastography (TE) have been broadly studied for the evaluation of cirrhosisor, fibrosis in modified studies based primarily on viral hepatitis patients. Magnetic resonance elastography is one of the appearing methods with potential.

4. Genetic Biomarkers

With strong genetic and environmental effects, NAFLD is viewed as a complex disease characteristic. Our knowledge of the pathophysiology of disease has been enhanced by the genetic data from these studies. A couple of genetic variations such as rs58542926 and rs738409 and in the Patatin-like phospholipase domain containing 3 protein (PNPLA3) and Transmembrane 6 superfamily member 2 (TM6SF2) hepatic steallate changes have been connected with higher fat consumption [29,30]. Between 3.3% and 2% of NAFLD cases are linked to them. Yet, they are equivalent to other non-invasive indicators in their capacity to predict disease.

The MBOAT7-TMC4 locus's rs641738 C>T genetic mutation was subsequently connected to an increased risk of the whole spectrum of NAFLD [31].

The specific variation of DNA sequence, such as "single nucleotide polymorphisms”(SNPs), can still be used in clinical settings to identify people at risk of developing NAFLD with sufficient sensitivity, specificity, and predictive values of both positive and

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

negative [32]. This is true despite the importance of these genetic variant discoveries.

When the MAF of the TM6SF2 polymorphism (MAF 0.07) is taken into consideration, the risk effect of the common missense SNPs rs738409 in PNPLA3 and rs58542926 in TM6F2 is significantly smaller. MAFs, or minor allele frequencies, measure how frequently the second most prevalent allele appears in a population. They were 0.38.

5. Markers Based on OMICS

Via the relatively quick assessment of hundreds of metabolites, contemporary mass spectroscopy (MS) and very effective methods have promoted the identification of new biomarkers of NASH along with NAFLD. Despite proteomic technologies' ability to assess a large number of proteins in a small blood sample, a platform for evaluating the proteins that have an effect on NAFLD is not yet available. (Younussi et al.) [33] had observed peaks of12 proteins with notable differential expression by the severity of diagnosing NAFLD/NASH among98 patients that underwent bariatric surgery, however, they may not be representative of the entire population of NAFLD patients. In a different study of obese patients, Charlton et al. had shown that 9 proteins had conveyed in different amounts depending on study group [34]. In a study that was released in 2010, Bell et al. looked into a quantitative proteomics approach (LFQP) using 1738 proteins a label-free. Since that there was no apparent distinction between the NASH and simple steatosis subgroups, it may be more challenging to identify systemic indications of initial mild NASH in serum. Overall, between the basic steatosis and NASH F3/F4 groups, the expression of 55 of 605 proteins was different, and 15 proteins that might be useful as biomarkers were discovered. Using this serum panel, it has also been established that it can distinguish between people with NAFLD and those whose lives have been harmed by medication [35]. Proteomics was utilized by (Yu et al.) to show that values of higher baseline hemoglobin are related to the emerging NAFLD in a potential cohort of 6944 patients [36].

During themetabolic profiles of the blood of the patients with NASH or with simple steatosis and ActiveX controls were investigated, pyrogalactoside showed a promising accuracy rate of 82% in identifying NASH from groups of simple steatosis. [37].

Significant alterations of plasma lipid species in a range across the spectrum of NAFLD have been analyzed, in addition to research on bile acid biomarkers, making lipidomic appear to be a feasible strategy in NAFLD. Short-chain fatty acids (SCFAs) and Branch-chain amino acids (BCAAs) may undergo changes (BCAA). A significant sample of 679 patients that underwent a biopsy of the liver or MS was examined, and a signature made up of three lipid molecules was discovered and confirmed.

6. Biomarkers Relating to the Microbiota

Metabolites and gut microbiota linked to NASH, NAFLD, and fibrosis are examined as promising options for noninvasively diagnosing illness in its early stages. Dysbiosis, which is defined as a drop in the phyla Firmicutes, an increase in the phyla Proteobacteria, and a decrease in the phyla Ruminococcin, has been connected to fibrosis and NASH in numerous human studies [38].

7. Conclusion

The success of a preventative program depends on the early recognition of those related to high risk through the assessment of particular specific biomarkers. As strategies of treatment for patients suffering from NASH who are at risk of advancement are implemented, in order to screen biomarkers are needed and determining the response to medication. Early diagnosis has now been provided by MRI-PDFF and prognostic data on NAFLD, it is not generally accessible. A growing number of non-invasive imaging methods, including MRI, are being developed. Biomarkers of serum for diagnosing fibrosis in NASH are more effective at excluding cirrhosis and severe fibrosis than at correctly identifying various phases of fibrosis. Between the severity of NASH and patients with or without a NASH histological diagnosis, procollagen C3 levels provide a largely linear relationship. MRE is one of the most accurate imaging technologies, however, it is limited by the cost and time involved in the tests. Detection of patients earlier who are at the condition of developing advanced fibrosis may be aided by the use of new OMICS indicators. Yet, because of the challenging methodological application, their accuracy is limited. As a result, using a single marker

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

to differentiate NAFLD accurately from NASH and the severity of NASH of various is not achievable for selecting the best candidate for experimental studies. Combinations of the biomarkers with the best performing must be utilized in clinical studies of new therapeutic agents.

References

[1] J. A. López-Velázquez et al. The prevalence of nonalcoholic fatty liver disease in the Americas and Annals of Hepatology.2014;13 (2):166–78.

[2] Baranova A., Younossi Z.M. The future is around the corner: Noninvasive diagnosis of progressive nonalcoholic steatohepatitis. Hepatology. 2008;47:374–375. doi: 10.1002/hep.22140.

[3] Skelly M.M., James P.D., Ryder S.D. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J. Hepatol. 2001;35:195–199. doi: 10.1016/S0168-8278(01)00094-0.

[4] Pendino G.M., Mariano A., Surace P., Caserta C.A., Fiorillo M.T., Amante A., Bruno S., Mangano C., Polito I., Amato F., et al. Prevalence and etiology of altered liver tests: A population-based survey in a Mediterraneantown. Hepatology. 2005;41:1151–1159. doi: 10.1002/hep.20689.

[5] Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., Grundy S.M., Hobbs H.H. Prevalence of hepatic steatosis in an urban population in the United States: Impact ofethnicity. Hepatology. 2004;40:1387–1395. doi: 10.1002/hep.20466.

[6] Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference. Hepatology. 2003;37:1202–1219. doi: 10.1053/jhep.2003.50193.

[7] Sorrentino P., Tarantino G., Conca P., Perrella A., Terracciano M.L., Vecchione R., Gargiulo G., Gennarelli N., Lobello R. Silent non-alcoholic fatty liver disease-a clinical-histological study. J. Hepatol. 2004;41:751–757. doi: 10.1016/j.jhep.2004.07.010.

[8] Fracanzani A.L., Valenti L., Bugianesi E., Andreoletti M., Colli A., Vanni E., Bertelli C., Fatta E., Bignamini D., Marchesini G., et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes Hepatology. 2008;48:792–798. doi: 10.1002/hep.22429.

[9] Kotronen A., Peltonen M., Hakkarainen A., Sevastianova K., Bergholm R., Johansson L.M., Lundbom N., Rissanen A., Ridderstråle M., Groop L., et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137:865–872. doi: 10.1053/j.gastro.2009.06.005.

[10] Lee J.H., Kim D., Kim H.J., Lee C.H., Yang J.I., Kim W., Kim Y.J., Yoon J.H., Cho S.H., Sung M.W., et al. Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease. Dig. Liver Dis. 2010;42:503–508. doi: 10.1016/j.dld.2009.08.002.

[11] Bedogni G., Bellentani S., Miglioli L., Masutti F., Passalacqua M., Castiglione A., Tiribelli C. The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33. doi: 10.1186/1471-230X-6-33.

[12] Yokoo T., Byddar M., Hamilton G., Middleton M.S., Gamst A.C., Wolfson T., Hassanein T., Patton H.M., Lavine J.E., Schwimmer J.B., et al. Nonalcoholic Fatty Liver Disease: Diagnostic and Fat-Grading Accuracy of Low-Flip-Angle Multiecho Gradient-Recalled-Echo MR Imaging at 1.5 T. Radiology. 2009;251:67–76. doi: 10.1148/radiol.2511080666.

[13] Kang G., Cruite I., Shiehmorteza M., Wolfson T., Gamst A.C., Hamilton G., Bydder M., Middleton M.S., Sirlin C.B. Reproducibility of MRI-determined proton density fat fraction across two different MR scanner platforms. J. Magn. Reson. Imaging. 2011;34:928–934. doi: 10.1002/jmri.22701.

[14] Tang A., Tan J., Sun M., Hamilton G., Bydder M., Wolfson T., Gamst A.C., Middleton M., Brunt E.M., Loomba R., et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology. 2013;267:422–431. doi: 10.1148/radiol.12120896.

[15] Negrete L., Middleton M.S., Clark L., Wolfson T., Gamst A.C., Lam J., Changchien C., Deyoung-Dominguez I.M., Hamilton G., Loomba R., et al. Inter-examination precision of

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

magnitude-based MRI for estimation of segmental hepatic proton density fat fraction in obese subjects. J. Magn. Reson. Imaging. 2014;39:1265–1271. doi: 10.1002/jmri.24284.

[16] Middleton M.S., Heba E.R., Hooker C.A., Bashir M.R., Fowler K.J., Sandrasegaran K., Brunt E.M., Kleiner D.E., Doo E., Van Natta M.L., et al. Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with non-alcoholic steatohepatitis. Gastroenterology. 2017;153:753–761. doi: 10.1053/j.gastro.2017.06.005.

[17] Patel J., Bettencourt R., Cui J., Salotti J., Hooker J., Bhatt A., Hernandez C., Nguyen P., Aryafar H., Valasek M., et al. Association of non invasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Ther. Adv. Gastroenterol. 2016;9:692–701. doi: 10.1177/1756283X16656735

[18] Loomba R., Neuschwander B.A., Sanyal A., Chalasani N., Diehl A.M., Terrault N., Kowdley K., Dasarathy S., Kleiner D., Behling C., et al. Multicenter validation of association between decline in MRI-PDFF and histologic response in nonalcoholicstetohepatitis. Hepatology. 2020 doi: 10.1002/hep.31121. in press.

[19] Sasso M., Tengher-Barna I., Ziol M., Miette V., Fournier C., Sandrin L., Poupon R., Cardoso A.C., Marcellin P., Douvin C., et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan (R): Validation in chronic hepatitis C. J. Viral Hepat. 2012;19:244–253. doi: 10.1111/j.1365-2893.2011.01534.x.

[20] Karlas T., Petroff D., Sasso M., Fan J.G., Mi Y.Q., de Lédinghen V., Kumar M., Lupsor-Platon M., Han K.H., Cardoso A.C., et al. Individual patients data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J. Hepatol. 2017;66:1022–1030. doi: 10.1016/j.jhep.2016.12.022.

[21] De Ledinghen V., Wong G., Vergniol J., Chan H.L., Hiriart J.B., Chan A.W., Chermak F., Choi P.C., Foucher J., Chan C.K., et al. Controlled attenuation parameter for the diagnosis of steatosis in nonalcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2016;31:848–855. doi: 10.1111/jgh.13219.

[22] Boursier J., Fraysse J., Lafuma A., Torreton E., Ozbay A.B. Increased healthcare resource utilization and costs in non-acoholic fatty liver disease/non-acoholicsteatohepatitis patients with liver disease progression: A multivariate analysis of french national hospital care. J. Hepatol. 2019;70:e1–e44.

[23] Cusi K., Chang Z., Harrison S., Lomonaco R., Bril F., Orsak B., Ortiz-Lopez C., Hecht J., Feldstein A.E., Webb A., et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in aptients with non-alcoholic fatty liver disease. J. Hepatol. 2014;60:167–174. doi: 10.1016/j.jhep.2013.07.042.

[24] Poynard T., Ratziu V., Charlotte F., Messous D., Munteanu M., Imbert-Bismut F., Massard J., Bonyhay L., Tahiri M., Thabut D., et al. Diagnostic value of biochemical markers (NAShTest) for the prediction of nonalcoholic steatohepatitis in patients with non alcoholic fatty liver 2006. BMC Gastroenterol. 2006;10:6–34.

[25] Dowman J.K., Tomlinson J.W., Newsome P.N. Systematic review: The diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2011;33:525–540. doi: 10.1111/j.1365-2036.2010.04556.x

[26] Adams L.A., Feldstein A.E. Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis. J. Dig. Dis. 2011;12:10–16. doi: 10.1111/j.1751-2980.2010.00471.x.

[27] Younossi Z.M., Jarrar M., Nugent C., Randhawa M., Afendy M., Stepanova M., Rafiq N., Goodman Z., Chandhoke V., Baranova A. A novel diagnostic biomarker panel for obesity-related nonalcholic steatohepatitis (NASH) Obes. Surg. 2008;18:1430–1437. doi: 10.1007/s11695-008-9506-y.

[28] Rosenberg W.M., Voelker M., Thiel R., Becka M., Burt A., Schuppan D., Hubscher S., Roskams T., Pinzani M., Arthur M.J. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology. 2004;127:1704–1713.doi: 10.1053/j.gastro.2004.08.052.

[29] Romeo S., Kozlitina J., Xing C., Pertsemlidis A., Cox D., Pennacchio L.A., Boerwinkle E., Cohen

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

J.C., Hobbs H.H. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008;40:1461–1465. doi: 10.1038/ng.257.

[30] Kozlitina J., Smagris E., Stender S., Nordestgaard B.G., Zhou H.H., Tybjærg-Hansen A., Vogt T.F., Hobbs H.H., Cohen J.C. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2014;46:352–356. doi: 10.1038/ng.2901.

[31] Mancina R., Dongiovanni P., Petta S., Pingitore P., Meroni M., Rametta R., Borén J., Montalcini T., Pujia A., Wiklund O., et al. The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology. 2016;150:1219–1230. doi: 10.1053/j.gastro.2016.01.032

[32] Eslam M., Valenti L., Romeo S. Genetics and epigenetics of NAFLD and NASH. J. Hepatol. 2018;68:268–279. doi: 10.1016/j.jhep.2017.09.003

[33] Younossi Z.M., Baranova A., Ziegler K., Del Giacco L., Schlauch K., Born T.L., Elariny H., Gorreta F., VanMeter A., Younoszai A., et al. A genomic and proteomic study of the spectrum of non-alcoholic fatty liver disease. Hepatology. 2005;25:760–771.

[34] Charlton M., Viker K., Krishnan A., Sanderson S., Veldt B., Kaalsbeek A.J., Kendrick M., Thompson G., Que F., Swain J., et al. Differential expression of lumican and fatty acid binding protein-1-New insights into the histologic spectrum of non-alcoholic fatty liver disease. Hepatology. 2009;49:1375–1384. doi: 10.1002/hep.22927.

[35] Bell L.N., Theodorakis J.L., Vuppalanchi R., Saxena R., Bemis K.G., Wang M., Chalasani N. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology. 2010;51:111–120. doi: 10.1002/hep.23271.

[36] Bell L.N., Vuppalanchi R., Watkins P.B., Bonkovsky H.L., Serrano J., Fontana R.J., Wang M., Rochon J., Chalasani N. Serum proteomic profiling in patiets with drug-induced liver injury. Aliment. Pharmacol. Ther. 2012;35:600–612. doi: 10.1111/j.1365-2036.2011.04982.x

[37] Yu C., Xu C., Xu L., Yu J., Miao M., Li Y. Serum proteomic analy- sis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J. Hepatol. 2012;56:241–247. doi: 10.1016/j.jhep.2011.05.027.

[38] Suwen Q., Depeng X., Qiaoliang L., Xie N., Xia J., Huo Q., Li P., Chen Q. Metabolomics screening of serum identifies pyroglutamate as a diagnostic biomarker for nonalcoholic steatohepatitis. Clin. Chim. Acta. 2017;473:89–95.